TGF-beta receptor type 1 (or TGF-beta receptor type 2) (TGFBR1 (ALK5), TGFBR2)

The canonical TGF-beta signaling pathway begins when TGF-beta ligand is released from its latent extracellular complex and binds to the constitutively active TGF-beta receptor type II (TGFBR2), which then recruits and phosphorylates TGF-beta receptor type I (TGFBR1/ALK5). The activated receptor complex phosphorylates receptor-regulated Smad2/3 proteins, which oligomerize with Smad4 and translocate to the nucleus to regulate transcription of genes involved in cell proliferation, differentiation, apoptosis, immune responses, and tissue homeostasis. Dysregulation of TGF-beta signaling is implicated in cancer, fibrosis, immune disorders, and cardiovascular disease. Therapeutic targeting focuses on blocking TGFBR kinase activity or neutralizing the ligand to modulate these pathological processes. Note: For structured data entry or annotation, the correct targets are specific receptors TGF-beta receptor type 1 (TGFBR1/ALK5) and TGF-beta receptor type 2 (TGFBR2), not the "TGF-beta receptor signaling pathway" as a whole.

Other names

TGF-beta receptor type I (ALK5), TGFBR1TGF-beta receptor type II, TGFBR2

Kinase inhibition: Small molecule inhibitors targeting the kinase activity of TGFBR1 block downstream Smad2/3 activation; Ligand neutralization: Antibodies sequester active TGF-beta, preventing receptor activation; Ligand trap: Fusion proteins bind TGF-beta ligands to prevent receptor association